CGAS and cancer: Based on this suggestion, it would be also interesting to test the validity of standard of care treatments including radiotherapy (Cosper et al. 2022), DNA damaging agents (Cheung-Ong et al. 2013), endocrine therapy in hormone-driven cancers (Risbridger et al. 2010), and others, in combination with cGAS-STING blockage, as well as to evaluate recently FDA-approved agents in the genome integrity space such as PARP or ATR inhibitors, within the context of synthetic lethality and beyond (Mullard 2022).